Professor Kevin J. Zwezdaryk and Chandler H. Monk discuss CRISPR and diagnostics, focusing on the development of a portable ...

CRISPR stock decline is influenced by Editas Medicine's struggles, but CRSP remains strong with FDA approval and strategic ...

We recently published a list of the 12 Biotech Stocks with the Biggest Upside Potential. In this article, we are going to ...

With that in mind, let's consider two stocks that haven't performed well recently and are now near their 52-week lows but ...

If we assume all patients who began treatment with Casgevy last year progress to the administration stage, CRISPR and Vertex ...

SAN FRANCISCO — Eleven years ago, Editas launched as the first company built around the nascent gene editing technology CRISPR. Founded by Feng Zhang, George Church, and others and backed by ...

CRISPR Therapeutics has a 12-month low of $38.20 and a 12-month high of $91.10. The firm has a market cap of $3.52 billion, a price-to-earnings ratio of -14.59 and a beta of 1.68.

ZUG, Switzerland and BOSTON, Jan. 08, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious ...

CRISPR is a powerful gene-editing tool that holds enormous potential for treating genetic diseases by allowing scientists to ...

Some of the best possible returns for investors come by not going after megacaps, but instead pursuing stocks that have more ...

To fix the dysferlin mutation, Escobar uses CRISPR-Cas9, which is often described as “gene-editing scissors” and for which a Nobel Prize was awarded in 2020. The molecular scissors are guided to a ...